Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-०.२१%
१,०९१.५१
-२.३०
-०.२१%
—१,०९३.८११,०९६.५२१,१००.२२१,०९१.५१——
SIXC
Communications
SIXC
Communications
SIXC
+०.२२%
६१०.११
+१.३४
+०.२२%
—६०८.७७६०८.७७६१२.९७६०८.७७——
SIXE
Energy
SIXE
Energy
SIXE
-१.३४%
१,२३७.९८
-१६.८३
-१.३४%
—१,२५४.८११,२५३.०११,२५३.८७१,२२६.३३——
SIXI
Industrials
SIXI
Industrials
SIXI
-०.९३%
१,७४४.७१
-१६.४०
-०.९३%
—१,७६१.१११,७६४.२७१,७६६.८८१,७४४.७१——
SIXM
Financials
SIXM
Financials
SIXM
-०.३७%
६४०.१८
-२.४०
-०.३७%
—६४२.५८६४४.८७६४८.४८६४०.१८——
SIXR
Staples
SIXR
Staples
SIXR
-०.१८%
८४९.५८
-१.५५
-०.१८%
—८५१.१३८५५.६६८५८.७५८४५.५६——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-०.२३%
२१७.४८
-०.५०
-०.२३%
—२१७.९८२१७.९८२१८.६५२१६.८८——
SIXT
Technology
SIXT
Technology
SIXT
+१.५२%
३,२६०.६९
+४८.८६
+१.५२%
—३,२११.८३३,२२७.२१३,२६८.३८३,२२६.५५——
SIXU
Utilities
SIXU
Utilities
SIXU
-०.६९%
९४२.४५
-६.५३
-०.६९%
—९४८.९८९४८.५८९५७.८३९४१.९७——
SIXV
Health care
SIXV
Health care
SIXV
-०.५२%
१,४६६.८०
-७.७२
-०.५२%
—१,४७४.५२१,४७९.०३१,४८१.०४१,४६६.८०——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+०.२२%
२,३९७.५०
+५.३८
+०.२२%
—२,३९२.१२२,३९६.९५२,४२१.२२२,३८२.३२——
Q1 2026 earnings • released • EPS beat +२३.६१% • Revenue beat +१०.३२%
See results
BIIB:NASDAQ
Biogen Inc
US$ १८७.०६
-१.१७%
(-२.२२) 1D
US$ १८७.१७
+०.०६% (+०.११)
After hours
Closed: मे १, १६:००:०१ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BIIB...
Open
US$ १८९.२८
High
US$ १९०.५७
Low
US$ १८६.१४
Mkt. cap
२७.६२ अरब
Avg. vol.
१२.०७ लाख
Volume
६.९७ लाख
P/E ratio
२०.०७
52-wk high
US$ २०२.४१
52-wk low
US$ ११५.२८
EPS
US$ ९.३२
Beta
०.१६
Shares outstanding
१४.७६ करोड
No. of employees
८ हजार
News stories
From sources across the web
GuruFocus
GuruFocus
·
५ घण्टा पहिले
BIIB Maintains Rating by Citigroup -- Price Target Raised to $20
Investing.com
Investing.com
·
७ घण्टा पहिले
Freedom Broker upgrades Biogen stock rating on Apellis acquisition
Simply Wall Street
Simply Wall Street
·
१० घण्टा पहिले
Assessing Biogen (BIIB) Valuation After Strong 1 Year Gains And Mixed Longer Term Returns
The Globe and Mail
The Globe and Mail
·
१२ घण्टा पहिले
Morgan Stanley Remains a Hold on Biogen (BIIB)
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc
CEOChris Viehbacher
Employees७.५ हजार
Founded१९७८
Headquartersक्याम्ब्रिज, म्यासेचुसेट्स, संयुक्त राज्य अमेरिका
Sector-
Websitebiogen.com
Last report
२०२६ अप्रिल २९
Fiscal Period
Q1 2026
Normalized EPS / Estimate
३.५७/ (२.८९ est.)USD
+२३.६१%beat
Revenue / Estimate
२.४८ अरब/ (२.२५ अरब est.)USD
+१०.३२%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
२०२५ जुन
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
Revenue
२.६५ अरब
२.५३ अरब
२.२८ अरब
२.४८ अरब
Cost of goods sold
९४.६२ करोड
५०.८६ करोड
४४.३४ करोड
६१.०२ करोड
Cost of revenue
९४.६२ करोड
५०.८६ करोड
४४.३४ करोड
६१.०२ करोड
Research and development expenses
-
४३.१८ करोड
५०.१० करोड
४८.२२ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
५८.१३ करोड
५९.२८ करोड
६८.५२ करोड
६०.७३ करोड
Operating expense
७८.३७ करोड
१.२५ अरब
१.३९ अरब
१.३० अरब
Total operating expenses
१.७३ अरब
१.७६ अरब
१.८३ अरब
१.९१ अरब
Operating income
९१.५६ करोड
७७.८६ करोड
४४.७७ करोड
५६.७४ करोड
Other non operating income
-३३.०० लाख
१.५८ करोड
१.७४ करोड
-११.०० लाख
EBT including unusual items
७४.४० करोड
५५.७३ करोड
-५.६० करोड
३७.७७ करोड
EBT excluding unusual items
८६.१६ करोड
७४.८३ करोड
४२.३१ करोड
५३.०१ करोड
Income tax expense
१०.९२ करोड
९.०८ करोड
-७१.०० लाख
५.८२ करोड
Effective tax rate
१४.६८%
१६.२९%
१२.६८%
१५.४१%
Other operating expenses
७.५० करोड
८.७२ करोड
६.९९ करोड
७.४२ करोड
Net income
६३.४८ करोड
४६.६५ करोड
-४.८९ करोड
३१.९५ करोड
Net profit margin
२४.००%
१८.४०%
-२.१५%
१२.८९%
Earnings per share
५.४७
४.८१
१.९९
३.५७
Interest and investment income
३.२३ करोड
३.१६ करोड
३.७२ करोड
३.७९ करोड
Interest expense
-७.२६ करोड
-६.७४ करोड
-६.७५ करोड
-६.७६ करोड
Net interest expenses
-४.०३ करोड
-३.५८ करोड
-३.०३ करोड
-२.९७ करोड
Depreciation and amortization charges
-
-
-
-
EBITDA
१.११ अरब
९८.०८ करोड
६४.७९ करोड
७७.१८ करोड
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer